Pharmion and MethylGene in $272 million cancer drug deal
‘Pharmion and MethylGene has announced the formation of an international licensing agreement potentially worth $272 million (€224 million) for new class of compounds that inhibits gene expression providing a tumour and haematological malignancy treatment platform.
The agreement represents a growing band of companies that see epigenetic control of cancer as the way forward treatment-wise. Epigenetics refers to changes in the regulation of gene expression. Epigenetic changes can silence gene expression and, unlike DNA mutations, may be reversed by targeting the enzymes involved.’
Read more at Pharmion and MethylGene in $272 million cancer drug deal
Recent Entries
- Sigma Pharmaceuticals year profit rises 27 pct
- South African citizens cheap drug guinea pigs
- Two drugs test victims face a year in coma
- Can drug companies improve their reputation?
- Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
- Pfizer’s Forecast Disappoints
- Pharmaceutical RFID Adoption Stalls
- Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
- GlaxoSmithKline unveils best results since merger
- Pfizer Sues Teva, Sandoz Over Zithromax